Episode
Update on Reproxalap PDUFA Timing
- Podcast
- Eyewire News: The Podcast
- Published
- Dec 17, 2025
- Duration seconds
- 531
- Processing state
not_requested- Canonical source
- https://traffic.megaphone.fm/BMCL3681770584.mp3
Actions
POST https://stenobird.com/v1/public/podcasts/eyewire-news-the-podcast-7055536/episodes/update-on-reproxalap-pdufa-timing/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/eyewire-news-the-podcast-7055536/update-on-reproxalap-pdufa-timing.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Aldeyra provides an update on the timing of its dry eye disease treatment candidate reproxalap; Ocular Therapeutix pursues an accelerated NDA pathway for wet AMD therapy Axpaxli; and companies with late-stage drug candidates announce FDA submission plans. Learn more about your ad choices. Visit megaphone.fm/adchoices